Obesity

US prevalence of optimal cardiometabolic health has declined as poor levels have risen significantly over 2 decades. Investigator Meghan O'Hearn, MS, details the research.

Insurance companies believe the required presurgical programs reduce complications and improve outcomes but a new study strongly suggests the opposite.

ENDO 2022: Findings from the long-term, real-world study of meds for maintenance of meaningful weight loss support wider uptake of the agents, authors say.

ADA 2022: Professor Hiddo Heerspink led the prespecified SURPASS-4 analysis that found tirzepatide associated with a 41% reduction in risk of a composite renal outcome.

Understanding the interplay between obesity and depression in children is key for clinicians to best advise this patient population. An overview, here.

Tirzepatide, a novel once-weekly GLP-1/GIP mimetic that binds to receptors and stimulates glucose-dependent insulin release, has shown superiority over many common antihyperglycemics.

The Canadian Obesity Society advocates for a therapeutic approach to obesity that removes stigma, focuses on individual patient goals, and favors body health over body weight.

Women, Black individuals, and adults diagnosed with overweight or obesity in more recent years were more likely to receive a referral, according to new study.

The proportion of overweight, obesity, or severe obesity increased from 38% to 45% among 4500 young people seen in a primary care network where most receive public insurance.

Obesity requires a spectrum of treatment options for effective results. Here, 3 key points to keep in mind when considering antiobesity medication for patients.